RADIANT offers mixed results for adjuvant erlotinib in NSCLC
July 9, 2014|Hematology and Oncology
Author and Disclosure Information
AT THE ASCO ANNUAL MEETING 2014
"I know that other experts have been using erlotinib in the adjuvant setting, though, off of a clinical trial," he said. "I’ve struggled with the issue, but I don’t think I’m ready to go there yet."
Dr. Kelly said the safety profile of erlotinib was generally consistent with that observed in the advanced disease setting and that additional biomarker analyses are ongoing.
Dr. Kelly and Dr. Hanna reported no relevant disclosures. Several coauthors reported financial relationships with Astellas Pharma, Roche, OSI Pharmaceuticals, or Novella Clinical.
